Investigator Payments – A Critical Component in Bayer’s Sponsor of Choice Strategy



Tuesday, July 20, 2021 at 11am EDT It’s not often that a sponsor calls a clinical trial solution “life-changing,” but that’s how Bayer is describing the impact of IQVIA Clinical Trial Payments as the solution rolls out to more than 20 countries. Learn how it’s possible to pay sites 2-3 times faster, eliminate end-of-study reconciliation, and reduce time spent supporting payment processes by up to 90%.

Register Free:

Event overview:

Becoming a partner of choice is a goal for many sponsors, and it all starts with a keen focus on removing the difficulties of trials for sites. Why then do slow and unpredictable clinical trial payments continue to be the #1 complaint from sites, year after year?

According to Mark Ryan, VP and Head of Site Management in the America’s for Bayer Healthcare Pharmaceuticals, the Payments solution you choose makes all the difference. Without the right expertise behind it, technology can complicate the process and potentially make it even more difficult than paying sites manually. Join this 60-minute webinar hosted by the payment teams from Bayer and IQVIA Technologies to learn why.

3 Key take-aways

  1. Hear the latest updates on Bayer’s ambitious project called ASPIREs – Automated Site Payment and Invoice Resolution – as it rolls out to more than 20 countries
  2. Learn the importance of choosing a partner that can advise you on what’s possible in each country to maximize automation and transparency
  3. Understand the magnitude of benefits achievable for sponsors from a solution that gets sites paid quickly and reliably


Mark Ryan
Vice President, Head of Site Management Americas
Bayer Pharmaceuticals

Mark has worked in the pharma industry for over 25 years. While most of his career has been in clinical operations, he also spent time working on process re-engineering. Mark is currently VP, Head of Site Management, Americas Region. His oversight includes Canada, the US and LATAM. His group is responsible for all Phase I-III clinical trials across various therapeutic areas including Cardiovascular, Women’s Healthcare & Oncology. Prior to his time at Bayer, Mark was a study coordinator at a clinical research site. Mark holds a BA in Psychology from Penn State University and an MBA from the University of New Haven.

Geri Masessa
Director, Resource Management
Bayer Healthcare

Geri has worked in the pharma industry for over 23 years, and at Bayer for 13 of those years. She started at Bayer as the US R&D Controller and then moved into a role as Director in Resource Management. Here, she supports the Oncology clinical teams with multiple tasks surrounding budgeting and planning clinical trials. Geri holds a Masters of Business Administration in Finance from Monmouth University.

Stuart Thiede
VP and Global Head, IQVIA Financial Lifecycle Solutions
IQVIA Technologies

Stuart Thiede is responsible for leading the international team of professionals that delivers investigator grant payment solutions to clinical trial sponsors and CROs. He was Senior VP of Global Payment Services at CFS Clinical when it was acquired by DrugDev in 2014, and continued to lead and grow the Clinical Trial Payments offering after DrugDev was acquired by IQVIA in 2017.

Stuart’s diverse background includes executive roles in finance, operations, service delivery, and account management in enterprises ranging from Fortune 500 technology companies to start-ups. He has significant international experience, including an expatriate assignment in Europe and a finance director role for a Latin American division of Unisys Corporation. Stuart has a B.S. in Accounting and an M.B.A. from Bowling Green State University.

Register Free:

Related Content
© 2024 MJH Life Sciences

All rights reserved.